Exenatide
 |
|
| Clinical data | |
|---|---|
| Trade names | Byetta, Bydureon |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605034 |
| Pregnancy category |
|
| Routes of administration |
subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Metabolism | proteolysis |
| Biological half-life | 2.4 h |
| Excretion | renal/proteolysis |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| KEGG | |
| ECHA InfoCard | 100.212.123 |
| Chemical and physical data | |
| Formula | C184H282N50O60S |
| Molar mass | 4186.6 g/mol |
  (what is this?)
|
|
Exenatide (
i/ɛɡzˈɛnətaɪd/, INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon. It is manufactured by Amylin Pharmaceuticals and commercialized by AstraZeneca.
Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster that was first isolated by John Eng MD in 1992 while working at the Veterans Administration Medical Center in the Bronx, New York. It displays biological properties similar to human glucagon-like peptide-1 (GLP-1), a regulator of glucose metabolism and insulin secretion. According to the package insert, exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying, although the mechanism of action is still under study.
...
Wikipedia